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Abstract
Background: Immune related adverse events (irAEs) are common side effects of checkpoint inhibitory (CPI)
therapies targeting CTLA-4 and PD-1/PD-L1. Grover’s disease is an uncommon dermatologic condition with
unclear pathogenesis previously reported as an irAE with ipilimumab.
Case Presentation: We report an additional case of ipilimumab-induced Grover’s disease. Interestingly, this
dermatologic side effect did not appear with use of anti-PD-1 therapy in our patient. Immune analysis was
performed and suggests a possible role of Th2 cells in its patholgenesis.
Conclusion: This case suggests that Grover's disease is an irAE induced by Ipilimumab. Our immune analysis
suggests that Th2 cells may be pathogenic mediators which warrants further study.
Background
Grover’s Disease, or transient acantholytic dermatosis,
was first described in 1970 in 6 patients presenting with
an unusual pruritic, papulovesicular dermatosis [1].
Thereafter, retrospective studies described the disease’s
distinct clinicopathologic features. Predominantly on the
trunk, back and extremities in adults over 40 years of
age, the distinctive skin lesions typically present with a
variety of histologic patterns (like pemphigus, Darier,
and Hailey-Hailey) that mimic other acantholytic
dermatoses [2, 3]. Given its rarity, the disease’s pre-
cise etiology and pathogenesis remains unclear but
studies have suggested numerous entities, including
drugs (recombinant IL-4; RAF inhibitors), solid and
hematologic malignancies, organ transplantation, ul-
traviolent exposure and heat [4–7]. Recently, Grover’s
disease was reported in a patient with metastatic mel-
anoma treated with ipilimumab [8].
Here, we report another case of ipilimumab-induced
Grover’s disease and provide a possible immunological
mechanism underlying the disease’s pathogenesis in rela-
tionship to CTLA-4, but not PD-1 inhibition. To our
knowledge, there are no other cases describing this im-
munologic mechanism for ipilimumab-induced Grover’s
disease in the medical literature.
Case presentation
A 73 y/o male presented with stage IIA cutaneous mel-
anoma of the left shoulder and underwent surgical re-
section in 2003. In November 2012, he developed
bilateral lung nodules with no other metastatic sites. A
right lung biopsy at this time confirmed metastatic mel-
anoma. He initiated therapy with ipilimumab at 3 mg/kg
IV every three weeks. After his second treatment dose,
he developed an intensely pruritic, papulovesicular rash
over his chest, bilateral upper extremities, and back.
Prior to this, the patient had no history of skin rashes.
He received methylprednisolone (40 mg IV initially, then
20 mg IV 1 month later without topical therapy) with
significant pruritus improvement; however, the rash
persisted. His outside physician then discontinued ipili-
mumab in March 2013 because of persistent rash symp-
toms and transitioned the patient to close observation.
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Remarkably, his lung nodules remained stable based on
CT imaging performed every six months.
In July 2014, we evaluated the patient for progressive
lung and liver metastases. He underwent a liver biopsy
that confirmed metastatic melanoma with mutations in
BRAF G466A and RET W917. Interestingly, he contin-
ued to have an extensive, erythematous, papular rash
over his chest, arms, and back that was asymptomatic
and had persisted since his previous ipilimumab therapy.
He had no other oral ulcers or skin lesions. A skin
biopsy was performed and histopathologic examination
revealed suprabasal acantholysis with associated overly-
ing dyskeratosis, consistent with Grover’s disease
(Fig. 1a-c). The acantholysis extended to the spinous
layer of the epidermis with some keratinocytes retaining
partial attachment to one another. In addition, there was
a superficial dermal mononuclear inflammatory infil-
trate. Immunohistochemical (IHC) studies demonstrated
a predominance of CD3+ T-cells with a predominance
of CD4+ over CD8+ T-cells (Fig. 1d-f). Because anti-PD-1
therapy had not been FDA-approved at the time, he
received systemic chemotherapy with disease progression.
Considering his BRAF G466A mutation, we subse-
quently initiated single agent trametinib but his
disease again progressed. Both chemotherapy and tra-
metinib were initiated after the patient’s repeat skin
biopsy.
Thereafter, we started pembrolizumab at 2 mg/kg IV
every three weeks. He tolerated therapy without signifi-
cant toxicities. His previous rash symptoms remained
stable during therapy with pembrolizumab. Unfortu-
nately, after two cycles he continued to have rapid,
progressive disease, and we discontinued therapy. Given
the previous favorable response with ipilimumab, we
re-initiated this therapy, but after one ipilimumab dose,
he experienced grade 2 rash exacerbation with an
intensely pruritic, papulovescular skin eruption on his
upper back. A repeat biopsy confirmed Grover’s disease
Fig. 1 Histopathologic and immunophenotypic studies of ipilimumab-induced Grover’s disease. a-c Scanning magnification of skin with acantholytic
dyskeratosis (a, H&E, 20×). Higher magnification reveals skin with suprabasal acantholysis and overlying dyskeratosis; (b, H&E, 100×) and (c, H&E, 40×).
Immunohistochemical studies demonstrate a predominance of CD3+ T-cells (d, anti-CD3, 100×) comprised of a predominance of CD4+ T-cells
(e, anti-CD4, 100×) over CD8+ T-cells (f, anti-CD8, 100×). Additional immunohistochemical studies demonstrate strong expression of PD-L1 by
the inflammatory cells (g, anti-PD-L1, 100×; inset, 400×). Scattered cells express PD-1 (h, anti-PD-1, 100×; inset 400×). There is scattered nuclear
expression of FoxP3 (i, anti-FoxP3, 100×; inset 400×) and T-beta (j, anti-T-Bet, 100×; inset, 400×) but strong diffuse nuclear expression of Gata-3
by the majority of the inflammatory cells as well as the overlying keratinocytes (k, anti-Gata-3, 100×; inset: 400×). Antibodies for RORgT are
essentially negative in the infiltrate. There is strong background staining in the skin tissue (l, anti-RORgT, 100×; inset: 400×)
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exacerbation. We started topical steroids and oral
antihistamines with minimal symptom improvement.
Thereafter, he received one additional ipilimumab dose
but transitioned to hospice after demonstrating terminal,
progressive disease. A treatment course timeline is
included as Fig. 2.
Discussion
Our case illustrates another example of ipilimumab-
induced Grover’s disease (transient acantholytic dyskera-
tosis). In our patient, there was a direct relationship
between onset of characteristic skin lesions with initial
ipilimumab administration and lesion exacerbation after
drug re-initiation. Remarkably, this immune finding does
not seem to be a universal consequence of all CPI
therapies as we observed stability of skin lesions with
pembrolizumab, a PD-1 inhibitor. Moreover, ipilimumab-
induced Grover’s disease appears to be a rare phenomenon
given the paucity of reported cases. Nevertheless, it is
important to emphasize that the histopathologic changes
seen here are indistinguishable from that seen in spor-
adic Grover’s disease.
IrAEs are common in patients treated with ipilimu-
mab. Phase 3 studies showed that the most common
ipilimumab-associated irAEs were dermatologic, gastro-
intestinal, endocrine, and hepatic in nature [9, 10].
While the pathogenesis of irAEs is unclear, CD4+ T-cells
have been shown to play a significant role [11]. Specific-
ally, T helper 17 cells (Th17), which are a distinct lineage
of CD4+ T-cells that produce characteristic cytokines
like IL-17 and IL-22, have been implicated in a variety of
autoimmune diseases and irAEs, particularly colitis [12].
Supporting this finding, pre-clinical studies have shown
that blocking the CTLA-4:B7 interaction on antigen
presenting cells and T cells, which is the mechanistic
action of ipilimumab, potentiates Th17 cell differenti-
ation in vivo and in vitro [12]. It is thought that blocking
this CTLA-4:B7 interaction with ipilimumab, therefore,
can potentiate Th17 mediated autoimmunity. In fact, a
recent study reported on the correlation between IL-17
up-regulation, and the development of immune related
colitis in patients treated with ipilimumab [13].
In our patient, IHC tissue analyses demonstrated
marked CD3+ lymphocyte infiltration and a predominance
of CD4+ over CD8+ T-cells (Fig. 1e-f). Additionally, there
was moderate expression of PD-1/PD-L1 (Fig. 1g-h). Con-
sidering the above hypothesis, this finding was expected.
However, analysis of protein expression using IHC of ca-
nonical transcription factors interestingly showed higher
GATA3 over T-Bet and RORgT (Fig. 1j-l). (GATA3, or
GATA-binding protein 3, is a Th2 transcription factor; T-
bet, or T box transcription factor, is a Th1 transcription
factor; and RORgT, or retinoic acid receptor-related or-
phan nuclear receptor, is a Th17 transcription factor).
There was also minimal FoxP3 expression, indicating
a limited contribution from Tregs (Fig. 1i). Taken to-
gether, these findings suggest that ipilimumab-induced
Grover’s disease may result from action of Th2 cells
with much less contribution from Th17. Moreover,
the finding that pembrolizumab therapy did not ex-
acerbate our patient’s Grover’s disease is consistent
with pre-clinical data demonstrating that PD-1 inhib-
ition induces Th1/Th17 responses while producing
less Th2 type responses [14].
In light of our patient’s clinical history with sup-
portive histologic and immunologic data, we believe
that ipilimumab-induced Grover’s disease is an irAE
that may be mediated by specific up-regulation and
infiltration of Th2 rather than Th17 cells. This aligns
with a previous report implicating IL-4, a known Th2
inducer, as a causative factor for Grover’s disease [7].
Having a deeper understanding of the characteristic
immune response that mediates irAEs, and specifically
dermatological irAEs in relation to Grover’s disease, may
have a tremendous impact on how we manage and
prevent them in a targeted way. As proof of concept,
Fig. 2 Chronologic timeline of patient’s clinical course
Uemura et al. Journal for ImmunoTherapy of Cancer  (2016) 4:55 Page 3 of 4
recent data has been published demonstrating the efficacy
of IL-17A inhibition in the treatment of psoriatic arthritis
[15]. Additionally, IL-6 receptor inhibitors are FDA
approved for autoimmune disorders like rheumatoid
arthritis and Crohn’s disease. This targeted approach to
immune suppression through selective inhibition of auto-
reactive cells like Th2/Th17 while minimally affecting the
tumor specific Th1/CD8 cells, may have better efficacy in
treating irAEs from CPI than generalized immune
suppression with corticosteroids, which is the current
practice. Furthermore, such an approach may preserve the
cytotoxic effect of CPI. Obviously, this hypothesis can be
confirmed only through prospective, randomized trials.
Our report also illustrates the increasing complexity and
wide variety of immune toxicities not experienced with
traditional therapies.
Conclusion
In conclusion, we report an addition case of Grover’s
disease induced by ipilimumab. Interestingly, this derma-
tologic side effect did not appear with use of anti-PD-1
therapy in our patient. Although its exact pathogenesis
is unknown, our immune analysis suggests a possible
role of Th2 cells, which may warrant additional study.
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